छोड़कर सामग्री पर जाएँ
TVS Q3FY24: Strong quarter, valuation at elevated levels

TVS Q3FY24: Strong quarter, valuation at elevated levels

With a solid product portfolio, strong market position, and a focus on electric vehicles, the company is expected to outperform the industry

Read More

​ With a solid product portfolio, strong market position, and a focus on electric vehicles, the company is expected to outperform the industry With a solid product portfolio, strong market position, and a focus on electric vehicles, the company is expected to outperform the industry  Moneycontrol Latest News Read More  

With a solid product portfolio, strong market position, and a focus on electric vehicles, the company is expected to outperform the industry

Glenmark inks licensing pact with Jiangsu Alphamab, 3D Medicines for cancer drug

Glenmark inks licensing pact with Jiangsu Alphamab, 3D Medicines for cancer drug

Under the agreement, Glenmark will get the license for KN035 (Envafolimab) in India, Asia Pacific, the Middle East, Africa, Russia, CIS, and Latin America, the company said in a statement.

Read More

​ Under the agreement, Glenmark will get the license for KN035 (Envafolimab) in India, Asia Pacific, the Middle East, Africa, Russia, CIS, and Latin America, the company said in a statement. Under the agreement, Glenmark will get the license for KN035 (Envafolimab) in India, Asia Pacific, the Middle East, Africa, Russia, CIS, and Latin America, the company said in a statement.  Moneycontrol Latest News Read More  

Under the agreement, Glenmark will get the license for KN035 (Envafolimab) in India, Asia Pacific, the Middle East, Africa, Russia, CIS, and Latin America, the company said in a statement.

hi_INहिन्दी
en_USEnglish hi_INहिन्दी